Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Sarcoma, Kaposi 3Lymphoproliferative Disorders 3Epstein-Barr Virus Infections 3Multi-centric Castleman's Disease 2Lymphoma 2Acquired Immunodeficiency Syndrome 2Stomach Neoplasms 1Pyloric Stenosis, Hypertrophic 1Neoplasms 1Nasopharyngeal Carcinoma 1Macular dystrophy, corneal type 1 1Lymphoma, Extranodal NK-T-Cell 1Lymphadenopathy 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Hodgkin Disease 1Head and Neck Neoplasms 1HIV Infections 1Glioblastoma 1EBV Lymphomas 1Cytomegalovirus Infections 1Castleman Disease 1Brain Neoplasms 1

Interventions

pegaspargase 15fludarabine phosphate 15Mycophenolic Acid 14Busulfan 14Tacrolimus 13Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 12Etoposide 12Dexamethasone 12Whole-Body Irradiation 11Methotrexate 10Gemcitabine 10Antilymphocyte Serum 9Radiotherapy 7Cyclosporine 7spartalizumab 6Oxaliplatin 5Asparaginase 5Transplantation 4Rituximab 4Melphalan 4Flow Cytometry 4tislelizumab 3thymoglobulin 3sintilimab 3selinexor 3pembrolizumab 3Therapeutics 3Polymerase Chain Reaction 3Cord Blood Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Extranodal NK-T-Cell × Valganciclovir × Clear all
NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

University of California, San Diego

Phase 2 Withdrawn
GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡